ArticleIrish journal of medical science2025
Prevalence of anti-nuclear antibodies in COVID-19 patients: a remarkable 2.5-fold rise compared to healthy controls.
Article in Irish journal of medical science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Magnitude of SARS-CoV-2 Antibody Production and Its Relationship with Autoantibody Formation.Infectious diseases & clinical microbiology · 2025Article
- COVID-19-associated Autoimmune and Inflammatory Diseases: Molecular Mechanisms and the Role of IVIG Therapy.Clinical reviews in allergy & immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe SARS-CoV-2 virus, responsible for COVID-19, has the potential to induce the formation of antibodies that target self-antigens. This study aimed to investigate the prevalence of antinuclear antibodies (ANA), the most common type of autoantibody, in both healthy individuals and those recovered from COVID-19.
methodsThis retrospective study involved 400 participants (200 with COVID-19 and 200 healthy controls), aged 18 to 60 years, without any chronic diseases, including autoimmune conditions. Analyses were performed using three different ANA ELISA test kits (anti-dsDNA, anti-ENA, and anti-Hep-2 nucleus tests) that were developed and validated.
resultsAmong the 200 healthy individuals, 38 (19%) tested positive for dsDNA, 37 (18.5%) for ENA, and 30 (15%) for Hep-2 nucleus antibodies. The rates of ANA positivity were significantly higher in individuals with COVID-19, with 97 (48.5%) positive for dsDNA, 81 (40.5%) for ENA, and 84 (42%) for Hep-2 nucleus antibodies (p < 0.05).
conclusionOne in every two to three individuals with COVID-19 exhibited ANA positivity, indicating that the SARS-CoV-2 virus poses a significant risk regarding autoimmunity. Furthermore, the incidence of ANA in healthy individuals was observed to be higher than the literature average.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.